Spots Global Cancer Trial Database for azd5363
Every month we try and update this database with for azd5363 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) Trial | NCT03182634 | Advanced Breast... | Fulvestrant Neratinib AZD5363 Olaparib AZD6738 | 18 Years - | Institute of Cancer Research, United Kingdom | |
| Trial of Olaparib in Combination With AZD5363 (ComPAKT) | NCT02338622 | Advanced Cancer | olaparib AZD5363 | 18 Years - | Royal Marsden NHS Foundation Trust | |
| National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer | NCT02664935 | Non-Small Cell ... Carcinoma, Squa... Adenocarcinoma | AZD4547 Vistusertib Palbociclib Crizotinib Selumetinib Docetaxel AZD5363 Osimertinib Durvalumab Sitravatinib AZD6738 | 18 Years - | University of Birmingham | |
| National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer | NCT02664935 | Non-Small Cell ... Carcinoma, Squa... Adenocarcinoma | AZD4547 Vistusertib Palbociclib Crizotinib Selumetinib Docetaxel AZD5363 Osimertinib Durvalumab Sitravatinib AZD6738 | 18 Years - | University of Birmingham | |
| AKT Inhibitor in Oestrogen Positive Breast Cancer | NCT02077569 | Invasive Breast... | AZD5363 | 18 Years - | University of Nottingham | |
| AKT Inhibitor in Oestrogen Positive Breast Cancer | NCT02077569 | Invasive Breast... | AZD5363 | 18 Years - | University of Nottingham | |
| SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer | NCT02299999 | Metastatic Brea... | AZD2014 AZD4547 AZD5363 AZD8931 Selumetinib Vandetanib Bicalutamide Olaparib Anthracyclines Taxanes cyclophosphamid... DNA intercalato... Methotrexate vinca alkaloids Platinum based ... Bevacizumab Mitomycin C Eribulin MEDI4736 | 18 Years - | UNICANCER | |
| Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies | NCT03772561 | Solid Tumor, Ad... | AZD5363+Olapari... | 21 Years - 99 Years | National University Hospital, Singapore | |
| SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients | NCT02117167 | Non-small Cell ... | AZD2014 AZD4547 AZD5363 AZD8931 Selumetinib Vandetanib Standard mainte... Pemetrexed Durvalumab savolitinib Olaparib | 18 Years - | UNICANCER | |
| OLAParib COmbinations | NCT02576444 | Cancer | AZD2281 AZD5363 AZD1775 AZD6738 | 18 Years - | Yale University | |
| Trial of Olaparib in Combination With AZD5363 (ComPAKT) | NCT02338622 | Advanced Cancer | olaparib AZD5363 | 18 Years - | Royal Marsden NHS Foundation Trust | |
| AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations | NCT03310541 | Breast Cancer Prostate Cancer Advanced Solid ... | AZD5363 Enzalutamide Fulvestrant | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Open Label Phase I/Randomised,Double Blind Phase II Study in mCRPC of AZD5363 In Combination With DP Chemotherapy | NCT02121639 | Prostate Cancer | Placebo AZD5363 | 18 Years - | University Hospital Southampton NHS Foundation Trust | |
| Open Label Phase I/Randomised,Double Blind Phase II Study in mCRPC of AZD5363 In Combination With DP Chemotherapy | NCT02121639 | Prostate Cancer | Placebo AZD5363 | 18 Years - | University Hospital Southampton NHS Foundation Trust | |
| Study of AZD5363 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring PIK3CA Mutation and/or PIK3CA Amplification as a Second-line Chemotherapy | NCT02451956 | Advanced Gastri... | AZD5363 paclitaxel | 20 Years - | Samsung Medical Center | |
| OLAParib COmbinations | NCT02576444 | Cancer | AZD2281 AZD5363 AZD1775 AZD6738 | 18 Years - | Yale University | |
| SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients | NCT02117167 | Non-small Cell ... | AZD2014 AZD4547 AZD5363 AZD8931 Selumetinib Vandetanib Standard mainte... Pemetrexed Durvalumab savolitinib Olaparib | 18 Years - | UNICANCER | |
| Comparison of Two Formulations of AZD5363 and the Effect of Food on Pharmacokinetic Exposure, Safety and Tolerability | NCT01895946 | Advanced Solid ... Safety and Tole... Pharmacokinetic... Tumour Response... | AZD5363 AZD5363 | 18 Years - 100 Years | AstraZeneca | |
| Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer | NCT01992952 | Estrogen Recept... | AZD5363 Placebo Fulvestrant | 18 Years - | Velindre NHS Trust | |
| Comparison of Two Formulations of AZD5363 and the Effect of Food on Pharmacokinetic Exposure, Safety and Tolerability | NCT01895946 | Advanced Solid ... Safety and Tole... Pharmacokinetic... Tumour Response... | AZD5363 AZD5363 | 18 Years - 100 Years | AstraZeneca | |
| PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer | NCT02423603 | Metastatic Brea... | Paclitaxel AZD5363 Placebo | 18 Years - | Queen Mary University of London |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
